Startups

Jun 1, 2020

NC State Spin-off TreeCo To Breed a Better Forest

A company founded by two NC State researchers is setting out to revolutionize the forestry industry by combining insights from tree genetics with the power of genome editing.

Jan 13, 2020

A world first: Triangle’s Locus Biosciences to launch major gene editing trial

RESEARCH TRIANGLE PARK – Morrisville-based Locus Biosciences, a developer of precision antibacterial therapies, will conduct the world’s first clinical trial of a recombinant bacteriophage therapy, a major milestone for the field, the company announced. Locus has opened enrollment for a Phase 1b trial of […]

Jun 4, 2019

NIRSleep — a startup led by an NC State alumnus, former employee — wins $25,000 in 2019 Lulu eGames

Less than four years ago, Casey Boutwell was a licensing associate for the Office of Research Commercialization, helping NC State faculty take their research from the lab into the marketplace. Now, he’s the CEO of Bionica Labs, a holding company for two […]

Apr 4, 2019

NIRvana Sciences Awarded $3 Million Phase IIb SBIR Grant from NIH

NIRvana Sciences, Inc., the leading developer of synthetic bacteriochlorins and chlorins, today announced that it has been awarded a $3 Million Phase IIb SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of […]

Feb 11, 2019

NC State Spinout Locus Biosciences Inks Historic Licensing Deal

NC State provides innovators with a range of programs and services to develop, protect, market and commercialize inventions developed at the university through the licensing of intellectual property or the launch of new companies based on university innovations. An example […]

Jan 3, 2019

Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics

Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage ("crPhage™") products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems.  Johnson & Johnson Innovation LLC facilitated the transaction.

Nov 28, 2018

Partner Profile: BRI Taps NC State Talent and Technology

Partnerships with NC State University’s research and academic programs have played a role in BioResource International’s success from the company’s start nearly 20 years ago – and they will in the future, as well.

Jul 19, 2018

Locus Biosciences acquires EpiBiome’s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics

Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.’s high-throughput bacteriophage (“phage”) discovery platform. Pairing EpiBiome’s powerful phage isolation and characterization capability with Locus’s CRISPR-based synthetic biology platform and clinical […]

Jun 14, 2018

Semiconductor firm HexaTech raises $2.7M in equity, wants $800,000 more

HexaTech, a spinout based on research into aluminum nitrides at North Carolina State University, is raising a new round of equity. According to a securities filing Thursday, the company has closed on $2.7 million in new cash from two investors. […]

May 23, 2018

NC State Pharma startup Emergo Therapeutics lands $12M from REX Health Ventures, Triangle backers

An all-star list of Triangle investors is backing Durham pharmaceutical startup Emergo Therapeutics with $12 million in venture capital. Leading the round, which was announced Wednesday, is REX Health Ventures. Other backers include: Wolfpack Investor Network Carolina Angel Network Hatteras Venture […]